Epigenetic Aging Clocks Predict Blood Clot Risk in Major Genetic Study
Large genetic analysis reveals how biological aging markers influence thrombosis risk, offering new prevention insights.
Summary
Researchers used genetic data from hundreds of thousands of people to investigate whether epigenetic aging—biological aging measured by DNA methylation patterns—causally influences blood clot risk. The study found that accelerated epigenetic aging reduces deep vein thrombosis risk, while certain aging-related proteins like FGF23 increase arterial clotting risk. Surprisingly, blood clots themselves may accelerate some forms of biological aging, suggesting a complex bidirectional relationship between aging processes and cardiovascular health.
Detailed Summary
Blood clots affect millions globally and remain a leading cause of death, but the relationship between biological aging and clotting risk has been unclear. This groundbreaking study used Mendelian randomization—a genetic technique that mimics randomized trials—to determine whether epigenetic aging causally influences thromboembolism risk.
Researchers analyzed genetic data from over 400,000 Europeans, examining multiple epigenetic aging clocks including PhenoAge, GrimAge, and HannumAge. These "clocks" measure biological age through DNA methylation patterns and can differ significantly from chronological age. The team also studied aging-related proteins like FGF23, PAI-1, and α-Klotho.
Key findings revealed unexpected complexity: intrinsic epigenetic age acceleration actually reduced deep vein thrombosis risk by 3.7%, while FGF23 protein levels increased arterial clotting risk by 66-68%. Most surprisingly, the relationship works both ways—portal vein thrombosis reduced PhenoAge by 12.9%, and venous thromboembolism increased GrimAge by 18.6%.
These results challenge assumptions about aging and clotting risk. The protective effect of some epigenetic aging markers against venous clots might reflect adaptive responses, while the bidirectional relationship suggests blood clots themselves may accelerate certain aging processes. This could explain why thrombosis survivors often experience accelerated health decline.
The findings have immediate clinical relevance for risk stratification and prevention strategies. However, the study was limited to European populations and couldn't account for lifestyle factors that influence both aging and clotting risk.
Key Findings
- Accelerated intrinsic epigenetic aging reduces deep vein thrombosis risk by 3.7%
- FGF23 protein increases arterial clotting risk by 66-68% in lower extremities
- Blood clots themselves accelerate biological aging measured by GrimAge clock
- Portal vein thrombosis reduces biological age measured by PhenoAge clock
- Bidirectional relationship exists between aging processes and clotting risk
Methodology
Two-sample Mendelian randomization using genetic variants as instruments to assess causality between epigenetic aging factors and thromboembolism in 400,000+ Europeans. Multiple sensitivity analyses excluded confounding and pleiotropy.
Study Limitations
Study limited to European populations, potentially limiting generalizability. Mendelian randomization cannot account for lifestyle factors that influence both aging and clotting risk. Some associations showed small effect sizes of uncertain clinical significance.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.